Dose escalation
Although part A of the study was principally designed for safety, a statistically significant dose-dependent efficacy of treatment was achieved, as assessed by ∆-change in C-peptide AUC. Treatment with ProTrans at a high dose (200 million cells) preserved beta cell function during the year of study when compared with low-dose treatment (25 million cells), as assessed by percentage ∆-change in C-peptide AUC (Fig. (